NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · CAH · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cardinal Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Cardinal Health, Inc.’s forward annual dividend is $2.06 per share, paid quarterly. The forward yield is 0.82% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Cardinal Health, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $2.94. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cardinal Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q3 2025 | May 1, 2025 | $2.35+8.29% vs estimate | $54.88B-0.93% vs estimate |
|---|
| Q2 2025 | Jan 30, 2025 | $1.93+10.92% vs estimate | $55.26B+0.45% vs estimate |
|---|
| Q1 2025 | Nov 1, 2024 | $1.88+16.05% vs estimate | $52.28B+2.72% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$980.88+$20.32 (+2.12%)
McKesson Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.79% below the high.
$330.53+$6.18 (+1.91%)
Cencora, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.45% below the high.
A$2.73+A$0.01 (+0.37%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.69% below the high.
$86.44+$1.48 (+1.74%)
Henry Schein, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.23% below the high.
CN¥16.45+CN¥0.02 (+0.12%)
Shanghai Pharmaceuticals Holding Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 11.37% below the high.
HK$16.21+HK$0.29 (+1.82%)
Sinopharm Group Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.53% below the high.
THE ANALYST VIEW
33 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $276.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
